{"nctId":"NCT00712985","briefTitle":"Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)","startDateStruct":{"date":"2005-09"},"conditions":["Breast Cancer"],"count":18,"armGroups":[{"label":"Zometa (Zoledronic Acid) X 1 dose","type":"EXPERIMENTAL","interventionNames":["Drug: Zometa"]}],"interventions":[{"name":"Zometa","otherNames":["Zoledronic Acid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Postmenopausal women with Stage I, II or IIIa breast cancer being treated with a non-steroidal Aromatase Inhibitor (AI) .Negative bone scan (no bone metastases).\n* Calculated creatinine clearance \\> 40 ml/min\n* Documented T score of less than or equal to -1.5 on Dual Energy X-ray Absorptiionmetry (DXA) scan at the lumbar spine or femoral neck within 3 months prior to screening.\n* Urine NTx \\> 50 nano moles(nM)based on second morning void.\n* Signed informed consent.\n* Ambulatory patients at least 18 years of age.\n* Eastern Cooperative Oncology Group (ECOG)0-2.\n* Ability to comply with trial requirements.\n\nExclusion Criteria:\n\n* Bone Metastases.\n* Any woman of child bearing potential.\n* Patients with fractures occurring within three months prior to randomization. - Greater than a 2+ protein on urine dipstick without evidence of contamination or bacteriuria (may be repeated one time, at least a day apart).\n* Calculated creatinine clearance less than 30 mL/min at screening.\n* Serum calcium \\> 2.75 mmol/L (11.0 mg/dL) or \\< 2.00 mmol/L (8.0 mg/dL).\n* Liver Function tests (LFT)\\> 2.0 x upper limit of normal (ULN).\n* Serum alkaline phosphatase \\> 1.5 x ULN. History of hypersensitivity to bisphosphonates.\n* Evidence of vitamin D deficiency (serum 25-(OH) D of less than 15 ng/ml).\n* History of uveitis or iritis, except when secondary to trauma, and must have resolved \\> 2 years prior to entry.\n* A history of invasive malignancy of any organ system, treated or untreated, within the past 12 months prior to screening; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed, Ductal Carcinoma in-situ (DCIS) that has been surgically removed, and Carcinoma in-situ (CIS) of the uterine cervix that has been surgically removed.\n* Previous major solid organ transplant recipient or on a transplant waiting list.\n* Treatment with any investigational drug within 30 days prior to randomization.\n* History of hyperparathyroidism, hypoparathyroidism, Osteogenesis imperfecta, Paget's disease or any metabolic bone disease other than osteoporosis.\n* Any medical condition which would interfere with the action of the study drug or limit life expectancy to less than 6 months.\n* Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial.\n* Prior treatment with IV bisphosphonates within the last 2 years.\n* Previous use of oral bisphosphonates within the past 2 years (unless used for less than 8 weeks\\*). \\*NOTE: If used less than 8 weeks, the washout period is 6 months.\n* Treatment with raloxifene, calcitonin, tibolone or hormone replacement therapy. The washout period for these medications is 6 months prior to randomization.\n* Any treatment with strontium ranelate, samarium, sodium fluoride or parathyroid hormone.\n* Use of systemic high dose corticosteroids at an average dose of \\> 7.5 mg per day of oral prednisone or equivalent for a period of three months or more prior to screening.\n* Known hypersensitivity to zoledronic acid or other bisphosphonates.\n* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.\n* Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Urine and Serum NTx and Serum CTx Within Normal Range at 12 Months","description":"17 women with early breast cancer receiving adjuvant Aromatase Inhibitor (AI) therapy were treated with a single 5 mg IV dose of zoledronic acid. Urine and serum NTx and serum CTx were measured at baseline and month 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":[]}}}